Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 35 of 38
LY293111 in Treating Patients With Advanced Solid Tumors
NCT00006375
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
NCT00102011
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
NCT00006019
PS-341 in Treating Patients With Hematologic Cancer
NCT00006098
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
NCT00006040
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
NCT00005860
Evaluation of the Compress Distal Femoral Replacement System
NCT00591812
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
NCT00005999
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
NCT00588328
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00006041
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy
NCT00006044
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
NCT00005618
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer
NCT00006038
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin
NCT00006043
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
NCT00005599
Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors
NCT00580463
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
NCT00005634
Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction
NCT00588510
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
NCT00005040
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
NCT00005069
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer
NCT00005814
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
NCT00005815
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
NCT00005637
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma
NCT00006039
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
NCT00005625
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
NCT00005805
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
NCT00005033
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
NCT00005636
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
NCT00005631
Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
NCT00005628
ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy
NCT00004926
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
NCT00004928
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
NCT00005638
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00005791
Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer
NCT00005616
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00005806
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
NCT00588289
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
NCT00004929
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
NCT00004891
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
NCT00004250
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
NCT00004215
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
NCT00004245
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
NCT00004110
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
NCT00004925
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
NCT00004059
BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00004877
Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases
NCT00004930
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
NCT00200174
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
NCT00004065
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer
NCT00005630
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.